Telix Pharmaceuticals (TLX: ASX) has announced a definitive agreement to acquire key assets from ImaginAb, a specialist in antibody engineering.
The deal will see Telix bolster its pipeline with early-stage therapeutic candidates and secure a state-of-the-art research facility in California to advance its innovation capabilities.
The acquisition includes drug candidates targeting DLL3, which are associated with unmet clinical needs, and several other targets in discovery stages. These assets complement Telix’s existing pipeline, which is focused on precision radiopharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze